Tetra Bio-Pharma news
"This important
- Panag Pharma Inc (Panag), a subsidiary of Tetra Bio-Pharma, will collect royalties on sales on products produced with the technology True North has licensed from Panag.
- Use of a highly innovative proprietary liposome encapsulated technology leads to a better CBD absorption.
- This New True North Nectar product line in liquid and powder formats are expected to launch in select markets in Q4 2022.
OTTAWA, ON, May 10, 2022&n
- Health Canada approved the amendment of the phase I study to assess the effect of low and moderate doses of inhaled CBD in healthy cannabinoid users.
- The collaboration with the CRCHUM will allow Tetra to obtain phase I clinical data on inhaled CBD.
OTTAWA, ON, March 8, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader
- The registration and commercialization
OTTAWA, ON, Dec. 21, 2021 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the closing of its marketed public offering (the "Offering") of 13,064,000 units of the Company (the "Units"), at a price of $0.163 per Unit for aggregate gross proceeds of $2.1 million. The Offering was co
- Tetra Bio-Pharma Confirms Meeting with the FDA to Align on the Requirements for Marketing Authorization
OTTAWA, ON, Nov. 29, 2021 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced that it received a letter from the United States Food and Drug Administration (FDA), granting a Type C meeting to discuss s
OTTAWA, ON, Oct. 14, 2021 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today provided an update on the progress and significant achievements of its lead investigational drug, QIXLEEF™.
QIXLEEF™ is a botanical inhaled drug product with a fixed ratio of THC and CBD that meets USA cGMP regulatory requirements. The drug
Halifax, Nova Scotia. Panag Pharma, Inc. launched a clinical trial evaluating the use of the newly NHP registered product Topical AOTC, a new generation topical for pain and pain associated with inflammation. Topical AOTC is a Health Canada approved natural health produc
Halifax, Nova Scotia. Panag Pharma Inc. announces that it has entered into a licensing agreement with Tetra Bio Pharma for its Topical ARx and Ocular products.
The Licensing Agreement provides for the continued development and commercialization of Panag’s unique produc